Last reviewed · How we verify
BAY86-6150
BAY86-6150 is a small molecule that inhibits the SGLT2 receptor.
BAY86-6150 is a small molecule that inhibits the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | BAY86-6150 |
|---|---|
| Sponsor | Bayer |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the SGLT2 receptor, BAY86-6150 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. The exact mechanism of action is not fully understood, but it is believed to involve the reduction of glucose reabsorption in the kidneys.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 (PHASE2, PHASE3)
- Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |